Despite surgery, radiation or chemotherapy or even a combination of all three treatment options, there is currently no cure for glioblastoma. In an earlier study the research group led by Professor Helmut Kettenmann (MDC) showed that neural precursor cells migrate to the glioblastoma cells and attack them. The neural precursor cells release a protein belonging to the family of BMP proteins (bone morphogenetic protein) that directly attacks the tumor stem cells. The current consensus of researchers is that tumor stem cells are the actual cause for continuous tumor self-renewal.
Kristin Stock, Jitender Kumar, Professor Kettenmann (all MDC), Dr. Michael Synowitz (MDC and Charité), Professor Rainer Glass (Munich University Hospitals, formerly MDC) and Professor Vincenzo Di Marzo (Istituto di Chimica Biomolecolare Pozzuoli, Naples, Italy) now report a new mechanism of action of NPC in astrocytomas. Like glioblastomas, astrocytomas are brain tumors that belong to the family of gliomas. Gliomas are most common in older people and are almost invariably fatal.
As the MDC researchers showed, the NPC also migrate to the astrocytomas. There they do not secrete proteins, but rather release fatty-acid substances (endovanilloids) which are harmful to the cancer cells. However, in order to exert their lethal effect, the endovanilloids need the aid of a specific ion channel, the TRPV1 channel (transient receptor potential vanilloid type 1), also called the vanilloid receptor 1. TRPV1 is already known to researchers as a transducer of painful stimuli. It has, among other things, a binding site for capsaicin, the irritant of hot chili peppers, and is responsible for the hot sensation after eating them. Clinical trials are currently underway to develop new pain treatments by blocking or desensitizing this ion channel.
MDC researchers describe an additional role of the TRPV1 ion channel
In contrast to its use in pain management, this ion channel, which is located on the surface of glioblastoma cells and is much more abundant there than on normal glial cells, must be activated to trigger cell death in gliomas. The activated ion channel mediates stress-induced cell-death in tumor cells. If however TRPV1 is downregulated or blocked, the glioma cells are not destroyed. The MDC researchers are thus the first to identify neural precursor cells as the source of fatty acids that induce tumor cell death and to describe the role of the TRPV1 ion channel in the fight against gliomas.
However, the activity of neural precursor cells in the brain and thus of the body’s own protective mechanism against gliomas diminishes with increasing age. This could explain why these tumors usually develop in older adults and not in children and young people. How can the natural protection of neural precursor cells be harnessed for older brains? According to the researchers, neural precursor cell therapy is not a solution. The benefit this obviously brings in the treatment of young people can have the opposite effect in older adults and may trigger brain tumors.
One possible treatment would be to use drugs to activate the TRPV1 channels. In mice, the group showed that a synthetic substance (arvanil), which is similar to capsaicin, reduced tumor growth. However, this substance has not yet been approved as a drug because the adverse side effects for humans are too severe. It is only used in basic research on mice, which tolerate the substance well. “In principle, however,” the researchers suggest, “synthetic vanilloid compounds may have clinical potential for brain tumor treatment.”
*Neural precursor cells induce cell-death of high-grade astrocytomas via stimulation of TRPV1
Kristin Stock1*; Jitender Kumar1*; Michael Synowitz1,2*; Stefania Petrosino3; Roberta Imperatore4; Ewan St. J. Smith5,6; Peter Wend7; Bettina Purfürst8; Ulrike A. Nuber9; Ulf Gurok10; Vitali Matyash1; Joo-Hee Wälzlein1; Sridhar R.Chirasani1; Gunnar Dittmar11; Benjamin F. Cravatt12, Stefan Momma13, Gary R. Lewin5, Alessia Ligresti3; Luciano De Petrocellis4; Luigia Cristino4; Vincenzo Di Marzo3; Helmut Kettenmann1*; Rainer Glass14*
*These authors contributed equally.
1 Cellular Neuroscience, 5 Molecular Physiology of Somatic Sensation, 7 Signal Transduction, Epithelial Differentiation, Invasion and Metastasis, 8 Central Facility for Electron Microscopy, 11 Central Facility for Mass Spectrometry; at the Max Delbrück Centre for Molecular Medicine (MDC), 13125 Berlin, Germany.
2 Department of Neurosurgery, Charité-Universitätsmedizin Berlin, 13353 Berlin, Germany.
3 Endocannabinoid Research Group, Institute of Biomolecular Chemistry, Consiglio Nazionale delle Ricerche, 80078 Pozzuoli (NA), Italy.
4 Endocannabinoid Research Group Institute of Cybernetics, Consiglio Nazionale delle Ricerche, 80078 Pozzuoli (NA), Italy.
6 Skirball Institute of Biomolecular Medicine, New York University Langone Medical Center, New York NY 10016
9 Lund Center for Stem Cell Biology and Cell Therapy, Lund University, SE-221 00 Lund, Sweden.
10 Max Planck Institute for Molecular Genetics, 14195 Berlin, Germany.
12 The Scripps Research Institute, SR107, 10550 North Torrey Pines Road, La Jolla, CA 92037
13 Restorative Neurology, Institute of Neurology (Edinger-Institute), Johann Wolfgang Goethe-University Frankfurt, 60528 Frankfurt am Main, Germany
14 Neurosurgical Research, Department of Neurosurgery, University of Munich, 81377 Munich, Germany
Max Delbrück Center for Molecular Medicine (MDC) Berlin-Buch
in the Helmholtz Association
Robert-Rössle-Straße 10; 13125 Berlin, Germany
Phone: +49 (0) 30 94 06 – 38 96; Fax: +49 (0) 30 94 06 – 38 33